Cargo Therapeutics, a Bay Area biotech firm, is laying off half its staff after having to shut down a promising drug ...

The future of the Bay Area biotech firm Allakos was riding on one clinical trial, for a drug designed to treat the skin ...

Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on ...

A year after reducing half of its workforce, Allakos will downsize to just 15 employees as it halts the development of AK006.

Leerink Partners analyst Thomas Smith has reiterated their neutral stance on ALLK stock, giving a Hold rating on January 27.Invest with ...

Allakos is throwing in the towel. After seeing phase 1 data in hives, the biotech has decided to drop the drug candidate and ...

Allakos, Inc. shares lost more than three-quarters of its market capitalization on Tuesday afternoon, marking a record low ...

The California-based company estimates that restructuring activities to close AK006 development will cost around $34 million to $38 million, with a major portion of these payments paid over in the ...

A Bay Area biotech firm is laying off 75% of its staff following a flopped clinical trial. Allakos, based in San Carlos, ...

Allakos halts AK006 development after phase 1 trial disappoints. Restructuring includes workforce cuts and $34 million-$38 ...

Citizens Jmp cut shares of Allakos (NASDAQ:ALLK – Free Report) from a strong-buy rating to a hold rating in a research note published on Monday,Zacks.com reports. Allakos Price Performance NASDAQ ALLK ...